Background Standard-of-care treatment for patients with newly diagnosed multiple
myeloma is bortezomib-based induction followed by high-dose melphalan and autologous …

Proteasome inhibitors have been associated with thrombotic microangiopathy (TMA) — a
group of disorders characterised by occlusive microvascular thrombosis causing …

Introduction: Carfilzomib (20/36mg/m 2 ) triplets with Lenalidomide-Dexamethasone (KRd),
or Cyclophosphamide-Dexamethasone (KCd) are safe and effective in patients with newly …

COVID-19–caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–has
spread to over 213 countries and territories, with 24,021,218 cases, including 821,462 …

Precision medicine holds great promise to improve outcomes in cancer, including
haematological malignancies. However, there are few biomarkers that influence choice of …

8000 Background: Upfront ASCT for NDTE MM remains under evaluation with high MRD
rates following novel induction and consolidation (cons) strategies. Current phase 3 trials …

Autologous stem cell transplant (ASCT) is the current standard of care for eligible patients
with multiple myeloma (MM). The UK national trial CARDAMON investigated whether, …

Background The role of upfront ASCT for NDTE MM remains under evaluation with high
MRD rates following novel induction and consolidation (cons) strategies. K maintenance …

Introduction: The role of front line ASCT remains under evaluation with the incorporation of
highly effective induction and salvage strategies. The Cardamon trial investigated if patients …

Introduction: Multiple myeloma remains an incurable disease with a significant variation in
therapeutic response. Choice of treatment is largely determined by prior lines of therapy and …